126 related articles for article (PubMed ID: 21497538)
1. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition.
Lekpa FK; Farrenq V; Canouï-Poitrine F; Paul M; Chevalier X; Bruckert R; Bastuji-Garin S; Claudepierre P
Joint Bone Spine; 2012 Jan; 79(1):47-50. PubMed ID: 21497538
[TBL] [Abstract][Full Text] [Related]
2. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.
Song IH; Heldmann F; Rudwaleit M; Haibel H; Weiss A; Braun J; Sieper J
Ann Rheum Dis; 2011 Jun; 70(6):1108-10. PubMed ID: 21415053
[TBL] [Abstract][Full Text] [Related]
3. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
[TBL] [Abstract][Full Text] [Related]
4. [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].
Brandt J; Westhoff G; Rudwaleit M; Listing J; Zink A; Braun J; Sieper J
Z Rheumatol; 2003 Jun; 62(3):264-73. PubMed ID: 12827403
[TBL] [Abstract][Full Text] [Related]
5. Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.
Canouï-Poitrine F; Poulain C; Molto A; Le Thuaut A; Lafon C; Farrenq V; Ferkal S; Le Corvoisier P; Ghaleh B; Bastuji-Garin S; Fautrel B; Dougados M; Claudepierre P
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1395-402. PubMed ID: 24664935
[TBL] [Abstract][Full Text] [Related]
6. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Sztajnbok F; Goldenstein-Schainberg C; Scheinberg M; Penades IC; Fischbach M; Orozco J; Hashkes PJ; Hom C; Jung L; Lepore L; Oliveira S; Wallace CA; Sigal LH; Block AJ; Covucci A; Martini A; Giannini EH; ;
Lancet; 2008 Aug; 372(9636):383-91. PubMed ID: 18632147
[TBL] [Abstract][Full Text] [Related]
7. High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies?
Berthelot JM; Tortellier L; Lavy-Bregeon D; Le Goff B; Maugars Y
Joint Bone Spine; 2008 Mar; 75(2):167-71. PubMed ID: 18296097
[TBL] [Abstract][Full Text] [Related]
8. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies.
Sulpice M; Deslandre CJ; Quartier P
Joint Bone Spine; 2009 Jan; 76(1):24-7. PubMed ID: 19070529
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
12. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.
Pham T; Fautrel B; Dernis E; Goupille P; Guillemin F; Le Loët X; Ravaud P; Claudepierre P; Miceli-Richard C; de Bandt M; Breban M; Maillefert JF; Masson C; Saraux A; Schaeverbeke T; Wendling D; Mariette X; Combe B;
Joint Bone Spine; 2007 Dec; 74(6):638-46. PubMed ID: 18065252
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for treating axial spondylarthropathy in everyday practice.
Griffoul I; Giraudeau B; Mulleman D; Benhamou CL; Valat JP; Goupille P
Joint Bone Spine; 2009 Jan; 76(1):39-43. PubMed ID: 19064331
[TBL] [Abstract][Full Text] [Related]
14. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients.
Gérard S; le Goff B; Maugars Y; Berthelot JM
Joint Bone Spine; 2008 Dec; 75(6):680-7. PubMed ID: 18848489
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
16. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis.
Zulian F; Balzarin M; Falcini F; Martini G; Alessio M; Cimaz R; Cimino L; Zannin ME
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):821-5. PubMed ID: 20191477
[TBL] [Abstract][Full Text] [Related]
17. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
[TBL] [Abstract][Full Text] [Related]
19. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
20. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
Brandt J; Haibel H; Reddig J; Sieper J; Braun J
J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
